Doctors question FDA approval of Gilead’s COVID-19 treatment and say it has limited benefits

The Food and Drug Administration’s decision to grant a full approval to Gilead Sciences Inc.’s remdesivir is raising questions about the broader value of a drug that has been praised for being ‘first’ but may only provide limited clinical benefits.